Renan Ozyerli, MD, MSD Turkey
Renan Ozyerli of MSD Turkey provides insights into the transformation of Turkey’s healthcare ecosystem over the past decade, highlighting how MSD works hand-in-hand with the government to broaden access to…
MSD entered the Turkish pharma market in 1989 and established a subsidiary in 1993.
The headquarters are based in Istanbul. MSD employs 463 people in Human Health, as well as 32 people in Animal Health. Products are sourced from the global MSD network and toll manufacturing from 4 local companies. The subsidiary has a fully operational warehouse.
Currently, MSD Turkey is participating in 23 international clinical trials at 113 study centers. As such, the affiliate ranks among the top 3 research-based pharma companies in terms of clinical research capability. MSD Turkey also houses the management oversight/responsibility of Middle East and Egypt with 6 trials and 21 study centers in 5 different countries. In 2014, Merck HQ funded TRY 20.7 million (USD 9.5 million) to Turkey for clinical trials.
Contact Details
Merck Sharp Dohme İlaçları Ltd. Şti.
Esentepe Mah. Büyükdere Cad. No: 199
Levent 199 Ofis Bloğu Kat: 13, 34394 Levent-İstanbul
Tel:+90 212 336 1000
Fax:+90 212 215 2733
http://www.msd.com.tr/
Renan Ozyerli of MSD Turkey provides insights into the transformation of Turkey’s healthcare ecosystem over the past decade, highlighting how MSD works hand-in-hand with the government to broaden access to…
MSD Turkey has benefited in recent years from the ability to engage in local business development initiatives, and managing director Hatice Demiray has prioritized initiatives such as reducing internal bureaucracy…
After an international career spanning 25 years, Demet Russ returned to her native Turkey to lead the Janssen affiliate during a tumultuous time and is aiming to give back to…
Avinash Potnis of Novartis Turkey discusses potential solutions to the country’s access and pricing dilemma which has raised concerns of system sustainability. Potnis also highlights the strengths of Turkey’s healthcare…
Ingrid Drechsel, head of Bayer’s pharma operations in Turkey and Iran, discusses the complexity of managing two countries under economic pressure and the advantages of Bayer’s longstanding relationship in both…
Menarini’s general manager for Turkey, the Middle East and Africa Uğur Bingöl discusses the Italian company’s restructuring in the region and its desire to replicate its success in Turkey across…
The secretary general for Turkey’s Pharmaceutical Manufacturers Association (IEIS), Savaş Malkoç, highlights their objective of increasing R&D expenditure and Turkey’s big opportunity ahead in biosimilars production. In addition, Malkoç discusses…
Janssen’s Managing Director for Turkey, Demet Russ, discusses her return to the country after 25 years abroad, having worked for Johnson & Johnson in different local, regional and global roles…
As one of the leading pharma companies in Turkey, DEVA is pioneering a new approach to generics in the country. Chairman of the Board and CEO Philipp Haas discusses the…
As COVID-19 began spreading through the world, the race to understand the disease by scientists and doctors took off. After just a few months, it became apparent that people with…
The president of the Turkish Society of Cardiology, Mustafa Kemal Erol, discusses the prevalence of cardiovascular disease, which accounts for over a third of deaths in Turkey, the improvements made…
AmCham Turkey’s executive director, Asli Özelli, examines the impact of US companies on the Turkish economy with over USD 50 billion in investment, their help during the pandemic, the chamber’s…
Dr Burak Cem, Novo Nordisk Vice President and General Manager for Turkey, outlines the company’s big bet on Turkey as a future regional hub through deep investment in clinical trials,…
Turkey’s former Minister of Health, Bülent Akarcali, outlines the country’s healthcare system evolution over the past decades, comparing the improvements to the difference between a Ford Model T to a…
See our Cookie Privacy Policy Here
